Antares Pharma, Inc. (ATRS)

[H2R]

QST meets Ph III Primary Endpoint!!!

See PDF here:
http://www.antarespharma.com/application/files/2714/9494/0285/AUA_Press_Release.pdf

Plus Midnight Trader:

Antares Pharma ( ATRS ) said a phase 3 study of its QuickShot testosterone auto injector met its primary endpoint, increasing testosterone levels in men with hypogonadism.
The company will present phase 3 data on the pharmacokinetics and safety of QuickShot at the American Urological Association annual meeting in Boston, Massachusetts May 16.

"A starting dose of 75 mg testosterone enanthate via auto injector, followed by a week-6 dose adjustment if necessary, was shown to achieve normal T levels when dosed weekly for 12 weeks in men with hypogonadism," the company said. "The treatment was well tolerated and the safety profile was consistent with the class."

Antares said it is working toward U.S.Food and Drug Administration approval in Q4.